US EditionPopularity of Psilocybin, Psychedelics Hasn't Increased ER Visits
Hallucinogens cause fewer than 2% of substance-related hospital visits in the US, with no rise linked to decriminalization policies, researchers reported.
- Recent analysis published in JAMA Network Open found that decriminalization of psychedelics in the US has not increased ER visits or hospitalizations, researchers reported.
- Using a large sample of patients treated for substance use, researchers tracked ER visits and hospital admissions among people 16–64 from 2016–2023, noting declines through 2023.
- Data show hallucinogens account for fewer than 2% of substance visits, with monthly shares ranging from 0.6% in January 2016 to nearly 1.2% in January 2021 and stabilizing by 2023.
- Senior researcher Dr. Kevin Xu, assistant professor of psychiatry at Washington University School of Medicine, said admissions declined through 2023 with no link to decriminalization, while Richard Grucza of Saint Louis University said alcohol and opioids drive most harms.
- Several jurisdictions including Oregon, Colorado, and cities in Massachusetts, California, and Michigan have decriminalized psilocybin, and the report was published in JAMA Network Open recently; the Cleveland Clinic provides additional context on hallucinogens.
42 Articles
42 Articles
Chart: Home and Rent Price Changes in Global Cities (2015-2025)
See more visualizations like this on the Voronoi app. Use This Visualization Charted: Home and Rent Price Changes in Global Cities (2015-2025) See visuals like this from many other data creators on our Voronoi app. Download it for free on iOS or Android and discover incredible data-driven charts from a variety of trusted sources. Key Takeaways Miami leads all cities with 93.1% growth in real home prices over the last decade, far exceeding its …
InnerMost Launches to Evolve Psychedelic Therapy - Advancing Treatment, Access, and Knowledge in the Field
Uniting FDA-authorized trials, ketamine and Spravato therapy, therapist training, and community education under one roof, InnerMost brings a vital new resource, contributing to the field globally
InnerMost Launches to Evolve Psychedelic Therapy - Advancing Treatment, Access, and Knowledge in the Field
Uniting FDA-authorized trials, ketamine and Spravato therapy, therapist training, and community education under one roof, InnerMost brings a vital new resource, contributing to the field globally
Coverage Details
Bias Distribution
- 44% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
